

STAT3
β-Actin
1
2
3
4
5
6
7
8
9
10
11
12
Markers
Mw Novex
Mw Magic
H1975
Untreated
Liposome STAT3
Liposome Empty
Markers
Mw Novex
Mw Magic
HCC 827
Untreated
Liposome STAT3
Liposome Empty
220
120
100
80
60
50
40
30
Lane
Stat3/Actin
3
0.63
4
0.5
5
0.63
9
0.98
10
0.6
11
0.89

FIG. 1



H1975 cells
Cell viability (% untreated cells)
120%
100%
80%
60%
40%
20%
0%
0
50
100
150
200
L-STAT3 antisense, µg/mL
Sequence #1
Sequence #2
Sequence #3
Sequence #4

FIG. 2A



HCC827 cells
Cell viability (% untreated cells)
120%
100%
80%
60%
40%
20%
0%
0
50
100
150
200
L-STAT3 antisense, µg/mL
Sequence #1
Sequence #2
Sequence #3
Sequence #4

FIG. 2B



H358 cells
Cell viability (% untreated cells)
120%
100%
80%
60%
40%
20%
0%
0
50
100
150
200
L-STAT3 antisense µg/mL
Sequence #1
Sequence #2
Sequence #3
Sequence #4

FIG. 2C



Liposomal STAT3 antisense inhibits growth of leukemia cell lines
Viability (% of untreated cells)
DNAbilize drugs (micrograms/mL)
K-562
MV4-11
KASUMI-1
PBMC
K-562
MV4-11
KASUMI-1
PBMC
120
100
80
60
40
20
0
0
20
40
80
120
160
200

FIG. 3A



Liposomal STAT3 antisense inhibits growth of lymphoma cell lines
Viability (% of untreated cells)
DNAbilize drugs (micrograms/mL)
DOHH-2
SU-DHL-4
SU-DHL-6
SU-DHL-10
RL
DOHH-2
SU-DHL-4
SU-DHL-6
SU-DHL-10
RL
0
20
40
60
80
100
120
0
20
40
80
120
160
200

FIG. 3B